RenovoRx, Inc. cotiza a 1.21 USD y tiene una capitalización bursátil de $54M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -977.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for…
| Periodo | 2026-11 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.08 | $-0.08 | $-0.08 |
| Estimado | $-0.05 | $-0.08 | $-0.08 | $-0.08 |
| Sorpresa | — | +0.0% | +0.0% | +0.0% |
| Métrica | RNXT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 70.9% | 57.0% | +13.8% |
| Operating Margin | -1114.0% | -38.6% | -1075.4% |
| Net Margin | -994.5% | -33.6% | -960.9% |
| FCF Margin | -977.3% | -13.9% | -963.4% |
| ROE | -206.0% | -40.4% | -165.6% |
| ROA | -138.0% | -32.0% | -106.0% |
| Current Ratio | 4.02 | 2.84 | +1.18 |
| Debt / Equity | — | 0.28 | — |